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Childhood Secondhand Smoke Exposure Predicts 
Increased Risk for Adulthood Atrial Fibrillation 
(AF) After Adjustment for AF Risk Factors 
 
A study analyzed Framingham Offspring cohort 
participants with parents in the Original cohort with known 
smoking status during the offspring’s childhood, evaluated 
every 2-8 years and being under routine surveillance for 
incident AF. Of 2,816 Offspring cohort participants with 
at least 1 parent in the Original cohort, 82% were exposed 
to parental smoking. For every pack/day increase in 
parental smoking, there was an 18% increase in offspring 
AF incidence (adjusted hazard ratio - HR: 1.18; p=0.04). 
Additionally, parental smoking was a risk factor for 
offspring smoking (adjusted odds ratio - OR: 1.34; 
p<0.001). Offspring smoking mediated 17% of the 
relationship between parental smoking and offspring AF 
(Groh CA et al, J Am Coll Cardiol 2019; 74:1658-64).  
 
When Left Untreated, Severe Aortic Stenosis (AS) is 
Associated With Poor Long-Term Survival / But Also 
Moderate AS Confers Poor Survival Rates  
 
Among 16,129 (6.7%), 3,315 (1.4%), and 6,383 
(2.6%) patients had mild, moderate, and severe AS, 
respectively, on an adjusted basis (vs. no AS; 5-year 
mortality 19%), patients with mild to severe AS had an 
increasing risk of long-term mortality (adjusted hazard 
ratio: 1.44-2.09; p<0.001 for all comparisons). The 5-year 
mortality was 56% and 67%, respectively, in those with 
moderate AS (mean gradient 20.0-39.0 mmHg/peak 
velocity 3.0-3.9 m/s) and severe AS (≥40 mmHg, ≥4 m/s, 
or AV area<1 cm2 in low-flow, low-gradient severe AS). 
A markedly increased risk of death from all causes (5-year 
mortality >50%) and CV disease was evident from a mean 
AV gradient >20 mmHg (moderate AS) after adjusting for 
age, sex, LV systolic or diastolic dysfunction, and aortic 
regurgitation (Strange G et al, J Am Coll Cardiol 2019; 
74:1851-63).  
 
Premature (Age≤45 Years) Acute or Stable Obstructive 
Coronary Artery Disease (CAD) is an Aggressive 
Disease Despite the Currently Recommended 
Prevention Measures, With High Rates of Recurrent 
Events and Mortality 
 
Among 880 patients with premature CAD, aged 40.1 
± 5.7 years, mainly men, smokers, with a family history of 
CAD or hypercholesterolemia, at baseline presentation, 
91% underwent coronary revascularization, predominantly 
for acute MI (79%). Over 20 years, one-third (n = 264) of 
patients presented with a total of 399 ischemic events, and 
36% had at least a second recurrent event. MI was the most 
frequent first recurrent event (n=131 of 264), mostly 
related to new coronary lesions (17% vs 8%; p=0.01; 
hazard ratio - HR: 1.45 for new vs initial culprit lesion). 
All-cause death (n=55; 6.3%) occurred at 8.4 years 
(median time). Ethnic origin (sub-Saharan African vs. 
Caucasian, adjusted HR - adjHR: 1.95; p=0.02), 
inflammatory disease (adjHR: 1.58; p=0.03), and 
persistent smoking (adjHR: 2.32; p<0.01) were the 
strongest correlates of a first recurrent event. When 
considering all recurrent events, the same factors and 
Asian ethnicity predicted poor outcome, but persistent 
smoking had the greatest impact on prognosis (Collet J-P 
et al, J Am Coll Cardiol 2019; 74:1868-78). 
 
The Absolute Risk of Osteoporotic Fractures is Low 
Among Patients With Atrial Fibrillation on Oral 
Anticoagulants, But Direct Oral Anticoagulants 
(DOAC) Confer Lower Risk of Osteoporotic Fractures 
Compared With Vitamin K Antagonists (VKA)  
 
Among 37,350 patients, the absolute 2-year risk of any 
fracture was low among DOAC-treated patients (3.1%) 
and among VKA-treated patients (3.8%). DOAC was 
associated with a significantly lower relative risk of any 
fracture (hazard ratio - HR: 0.85), major osteoporotic 
fractures (HR: 0.85), and initiating osteoporotic 
medication (HR: 0.82). A combined endpoint showed that 
patients treated with DOAC had a significantly lower 
relative risk of experiencing any fracture or initiating 
osteoporosis medication (HR: 0.84) (Binding C et al, J Am 
Coll Cardiol 2019;74: 2150-8).  
 
GLASSY Substudy: Ticagrelor Monotherapy After 
1-Month DAPT Failed to Decrease Bleeding Risk 
as Compared With Conventional Treatment  
 
The GLOBAL LEADERS study randomly assigned 
15,991 patients undergoing PCI to 1-month dual 
antiplatelet therapy (DAPT) followed by 23-month 
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ticagrelor monotherapy or conventional 12-month DAPT 
followed by 12-month aspirin. A substudy of 7,585 
patients (3,794 in the experimental arm and 3,791 in the 
control arm) indicated that the 2-year coprimary efficacy 
endpoint (all-cause death, nonfatal MI, nonfatal stroke, or 
urgent target vessel revascularization) occurred in 271 
(7.14%) and in 319 (8.41%) patients in the experimental 
and conventional groups, respectively (rate ratio-RR: 
0.85), fulfilling noninferiority (p noninferiority<0.001), 
but not superiority (p superiority=0.0465). The rates of 
BARC 3 or 5 bleeding did not differ (RR: 1.00; p=0.986). 
A time-dependent treatment effect was observed with the 
experimental strategy being associated with a lower risk of 
MI (RR: 0.54; p interaction=0.062) and definite stent 
thrombosis (RR: 0.14; p interaction=0.007) after 1-year 
post-PCI (Franzone A et al, J Am Coll Cardiol 
2019;74:2223-34).  
 
Single-Arterial CABG, Employed in 85% of Patients, 
Was Associated With Increased Mortality, Myocardial 
Infarction, and Repeat Revascularization Overall 
Compared With Multiarterial CABG  
 
Of the 26,124 patients, 3,647 (14%) underwent 
multiarterial CABG. Single-arterial CABG patients were 
older (mean 68 vs 61 y; p<0.001), had more comorbidities, 
and received fewer bypass grafts (3.4 vs 3.6; p<0.001). 
After adjusting for baseline differences, multiarterial 
CABG was associated with lower 10-year mortality 
compared with single-arterial CABG in 3,588 propensity-
matched pairs (15.1% vs 17.3%; p=0.01). Multiarterial 
CABG was associated with lower 10-year myocardial 
infarction (hazard ratio-HR: 0.81) and lower 10-year 
reintervention rate (HR: 0.81) (Chikwe J et al, J Am Coll 
Cardiol 2019;74:2238-48).  
 
Worrisome Early Mortality Following AF Ablation 
Affected Nearly 1 in 200 Patients, With the Majority of 
Deaths Occurring During 30-Day Readmission / 
Procedural Complications, Congestive Heart Failure, 
and Low Hospital AF Ablation Volume Were 
Predictors of Early Mortality   
A total of 60,203 admission records of US (NY) 
patients undergoing catheter ablation of AF (1/2010 - 
8/2015) were analyzed. Early mortality following AF 
ablation occurred in 0.46% cases, with 54.3% of deaths 
occurring during readmission. From 2010 to 2015, 
quarterly rates of early mortality post-ablation increased 
from 0.25% to 1.35% (p<0.001). Median time from 
ablation to death was 11.6 days. After adjustment for age 
and comorbidities, procedural complications (adjusted 
odds ratio - aOR: 4.06; p<0.001), heart failure (aOR: 2.20; 
p=0.011) and low AF ablation hospital volume (aOR: 2.35; 
p=0.003) were associated with early mortality. 
Complications due to cardiac perforation (aOR: 2.98; 
p=0.007), other cardiac (aOR: 12.8; p<0.001), and 
neurologic etiologies (aOR: 8.72; p<0.001) were also 
associated with early mortality (Cheng EP et al, J Am Coll 
Cardiol 2019; 74:2254-64).  
 
DC Cardioversion (CV) is Feasible in High-Risk AF 
Patients With a Left Atrial Appendage Occlusion 
(LAAO) Device Without Need for Anticoagulation if 
Pre-Procedural TEE Shows Good Device Position, 
Absence of Device-Related Thrombus, and Peridevice 
Leak of ≤5 mm  
 
Among 148 patients (aged 72±7 years; 59% men) with 
an LAAO device who underwent CV for symptomatic AF 
or atrial flutter, device-related thrombus was seen by TEE 
in 2.7%. They were all successfully treated with oral 
anticoagulation (OAC) and were able to undergo CV after 
6-8 weeks. CV restored sinus rhythm in all patients. None 
of the patients had CV-related thromboembolic 
complications. A total of 22% of patients were newly 
started on OAC after CV. There was no difference in CV-
related complications between patients treated with or 
without OAC post-CV. Patients receiving OAC post-CV 
were found to undergo CV at an earlier time after 
implantation (3.6 months vs 8.6 months; p=0.003). Three 
TIAs, unrelated to CV, were found during follow-up. Over 
a median of 12.8 months, no device or left atrial 
thrombosis, device dislodgement, or a new device leak 
were observed. One patient died during follow-up due to 
noncardiac cause (Sharma SP et al, J Am Coll cardiol 
2019; 74:2267-74).  
 
ADVANCE CRT Exposes a Vulnerable Group of 
Heart Failure Patients: CRT Non-Respondents 
 
Of 1,524 patients (68 ± 12 years of age, 32% female, 
ischemic disease 39%), 74.3% received CRT-D devices, 
using mainly quadripolar LV leads (75%) deployed 
laterally (78%). Indications for CRT were wider than past 
trials. Among 1,327 evaluable patients, nonresponse was 
20% (greater age, comorbidities, ischemic disease, non-
LBBB, and lower %CRT pacing vs responders). Site 
definitions used mainly clinical criteria, and 
underestimated nonresponders by 35% compared with 
independent scoring. Overall, more site-defined 
nonresponders received treatment (55.9% vs. 38.3% of 
responders; p < 0.001) using medication changes and heart 
failure education, but device programming less frequently, 
while 44% of site-defined nonresponders received no 
additional treatment. Frequency and duration of 
hospitalizations, and death, among site-defined 
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nonresponders was significantly higher than responders 
(Varma N et al, J Am Coll Cardiol 2019; 74:2588-2603).  
 
Rare Genetic Variants Associated With Sudden 
Cardiac Death (SCD) in Adults 
 
Among the 1,200 SCD cases and controls, the authors 
identified 5,178 genetic variants and classified 14 as 
pathogenic or likely pathogenic. These 14 variants were 
present in 15 individuals, all of whom had experienced 
SCD, corresponding to a pathogenic variant prevalence of 
2.5% in cases and 0% in controls (p<0.0001). Among the 
4,525 participants of the prospective cohort study, 41 
(0.9%) carried a pathogenic or likely pathogenic variant 
and these individuals had 3.24-fold higher risk of 
cardiovascular death over a median follow-up of 14.3 
years (p=0.02) (Khera AV et al, J Am Coll Cardiol 
2019;74:2623–34).  
 
PADIT: In Patients with Implanted Cardiac Devices, 
Hospitalization for Infection Occurred in 0.90% 
Within 1 Year / Prior Procedures, Older Age, Reduced 
Renal Function, Immunocompromised, and Procedure 
Type Were Significant Predictors of Device Infection  
Device procedures were performed in 19,603 patients, 
and hospitalization for infection occurred in 177 (0.90%) 
within 1 year of follow-up. The final prediction model 
identified 5 independent predictors of device infection 
(prior procedures [P], age [A], depressed renal function 
[D], immunocompromised [I], and procedure type [T]) 
with an optimism-corrected C-statistic of 0.704. A PADIT 
risk score ranging from 0 to 15 points classified patients 
into low (0 to 4), intermediate (5 to 6) and high (≥7) risk 
groups with rates of hospitalization for infection of 0.51%, 
1.42%, and 3.41%, respectively (Birnie DH et al, J Am 
Coll Cardiol 2019;74:2845-54).  
 
CvLPRIT: The Lower Rate of MACE in the Complete 
Revascularization Group, Previously Seen at 1 Year, is 
Sustained to a Median of 5.6 Years / A Significant 
Difference in Composite All-Cause Death/MI Favors 
Complete Revascularization 
Over a median follow-up (achieved in >90% patients) 
of 5.6 years, the primary MACE endpoint rate was 24% in 
the complete revascularization group but 37.7% of the 
infarct-related artery–only group (hazard ratio-HR: 0.57; 
p=0.0079). The composite endpoint of all-cause death/MI 
was 10% in the complete revascularization group vs 18.5% 
in the infarct-related artery–only group (HR: 0.47; 
p=0.0175). In a landmark analysis (from 1 year to final 
follow-up), there was no significant difference between 
MACE, death/MI, and individual components of the 
primary endpoint (Gershlick AH et al, J Am Coll Cardiol 
2019;74: 3083-94).  
 
COMPLETE: Among Patients With STEMI and 
Multivessel Coronary Artery Disease, Complete 
Revascularization was Superior to Culprit-Lesion-
Only PCI in Reducing the Risk of CV Death or MI, and 
the Risk of CV Death, MI, or Ischemia-Driven 
Revascularization 
 
At a median of 3 years, the first coprimary outcome 
(CV death/MI) had occurred in 158 of the 2016 patients 
(7.8%) in the complete-revascularization group vs 213 of 
the 2025 patients (10.5%) in the culprit-lesion-only PCI 
group (hazard ratio-HR, 0.74; P=0.004). The second 
coprimary outcome (CV death/MI/revascularization) had 
occurred in 8.9% vs 16.7% (HR, 0.51; P<0.001). For both 
coprimary outcomes, the benefit of complete 
revascularization was consistently observed regardless of 
the intended timing of nonculprit-lesion PCI (Mehta SR et 
al, N Engl J Med 2019; 381:1411-21) 
 
In RCTs, Triglyceride Lowering Confers a Lower Risk 
of Major Vascular Events, Even After Adjustment for 
LDL-C Lowering, Albeit the Effect is Less Than That 
for LDL-C (Attenuated When REDUCE-IT is 
Excluded) / The Benefits of Marine-Derived Omega-3 
Fatty Acids, Particularly High-Dose Eicosapentaenoic 
Acid, Appear to Exceed Their Lipid-Lowering Effects  
Among 197,270 participants (24 trials) of nonstatin 
therapy compared with 177,088 participants (25 trials) of 
statin therapy, starting with non–high-density lipoprotein 
cholesterol, a surrogate for very-low-density lipoproteins 
and low-density lipoproteins, the risk ratio (RR) per 1-
mmol/L reduction in non–high-density lipoprotein 
cholesterol was 0.79 (P<0.0001; 0.78 per 40 mg/dL). In a 
multivariable meta-regression model that included terms 
for both LDL-C and triglyceride (surrogates for low-
density lipoproteins and very-low-density lipoproteins, 
respectively), the RR was 0.80 (P<0.0001) per 1-mmol/L 
(0.79 per 40 mg/dL) reduction in LDL-C and 0.84 
(P=0.0026) per 1-mmol/L (0.92 per 40 mg/dL) reduction 
in triglycerides. REDUCE-IT was a significant outlier and 
strongly influential trial in the meta-regression. When 
removed, the RRs became 0.79 (P<0.0001) per 1-mmol/L 
(0.78 per 40 mg/dL) reduction in LDL-C and 0.91 
(P=0.06) per 1-mmol/L (0.96 per 40 mg/dL) reduction in 
triglycerides. In regard to omega-3 dose, each 1 g/d 
eicosapentaenoic acid administered was associated with a 
7% relative risk reduction in major vascular events (RR, 
0.93; P<0.0001), whereas there was no significant 
association between the dose of docosahexaenoic acid and 
the relative risk reduction in major vascular events (RR 
0.96) (Marston NA et al, Circulation 2019;140:1308–17).  
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Targeting Deceleration Zones (DZ) Identified by 
Propagational Analysis of Ventricular Activation 
During Sinus Rhythm Using a Voltage-Independent 
High-Density Mapping Display Can Guide Ablation, 
Obviating Extensive Radiofrequency Delivery / 
Regions With Isochronal Crowding During Baseline 
Rhythm Were Predictive of VT Termination Sites, 
Providing Mechanistic Evidence that DZ are Highly 
Arrhythmogenic, Functioning as Niduses for Reentry  
In 120 patients (median age 65 years, 15% female, 
50% nonischemic, median ejection fraction 31%) 
undergoing 144 ablation procedures for scar-related VT 
(57% with prior ablation; epicardial access used in 59%), 
high-density mapping during baseline rhythm was 
identified an average of 2±1 DZ, which colocalized to 
successful termination sites in 95% of cases. The median 
radiofrequency application duration was 29 min to target 
DZ, representing ablation of 18% of the low-voltage area. 
At 12±10 months, 70% freedom from VT recurrence (80% 
in ischemic cardiomyopathy and 63% in nonischemic 
cardiomyopathy) was achieved, with an overall survival 
rate of 87% (Aziz Z et al Circulation 2019;140:1383–97).  
 
DAPA-HF: Among Patients With Heart Failure (HF) 
with Reduced Ejection Fraction, the Risk of Worsening 
HF or CV Death was Lower among those who Received 
Dapagliflozin vs Placebo, Regardless of Presence of 
Diabetes  
Among 4744 patients with NYHA class II-IV HF and 
ejection fraction of <40%, randomized to dapagliflozin (10 
mg qd) or placebo, added to recommended therapy, over a 
median of 18.2 months, the primary outcome (worsening 
HF or CV death) occurred in 16.3% in the dapagliflozin 
group and in 21.2% in the placebo group (hazard ratio-HR, 
0.74; P<0.001). A first worsening HF event occurred in 
10%) vs 13.7% (HR, 0.70). Death from CV causes 
occurred in 9.6% vs 11.5% (HR, 0.82); 11.6% and 13.9%, 
respectively, died from any cause (HR, 0.83). Findings in 
patients with diabetes were similar to those in patients 
without diabetes. The frequency of adverse events related 
to volume depletion, renal dysfunction, and hypoglycemia 
did not differ between treatment groups (McMurray JJV et 
al, N Engl J Med 2019; 381:1995-2008) 
 
DEFINE-HF: In Patients (With or Without Diabetes) 
With Heart Failure (HF) and Reduced Ejection 
Fraction, Use of Dapagliflozin Over 12 Weeks did not 
Alter NT-ProBNP But Led to Improvement in HF-
Related Health Status / Benefits of Dapagliflozin on 
Clinically Meaningful HF Measures Appear to Extend 
to Patients Without Type 2 Diabetes Mellitus  
Among 263 HF patients with LVEF ≤40%, NYHA 
class II-III, eGFR ≥30 mL/min/1.73m2, and elevated 
natriuretic peptides, randomized to dapagliflozin 10 mg 
daily or placebo for 12 weeks, there was no significant 
difference in average 6- and 12-week adjusted NT-proBNP 
with dapagliflozin vs placebo. However, for the second 
dual-primary outcome of a meaningful improvement in 
quality of life (QOL) score or NT-proBNP, 61.5% of 
dapagliflozin-treated patients met this end point vs 50.4% 
with placebo (adjusted OR 1.8, nominal P=0.039). This 
was attributable to both higher proportions of patients with 
≥5-point improvement in QOL score (42.9 vs 32.5%, 
adjusted OR 1.73), and ≥20% reduction in NT-proBNP (44 
vs 29.4%, adjusted OR 1.9) by 12 weeks. Results were 
consistent among patients with or without type 2 diabetes, 
and other prespecified subgroups (all Ps for interaction = 
NS) (Nassif ME et al, Circulation 2019;140:1463–76).  
 
PARAGON-HF: Sacubitril–Valsartan did not Lower 
Heart Failure (HF) Hospitalization Rate and CV Death 
Among Patients With HF and Ejection Fraction >45%  
There were 894 primary events in 526 patients in the 
sacubitril–valsartan group and 1009 primary events in 557 
patients in the valsartan group (rate ratio, 0.87; P=0.06). 
The incidence of death from CV causes was 8.5% in the 
sacubitril–valsartan group and 8.9% in the valsartan group 
(hazard ratio-HR, 0.95); there were 690 and 797 total 
hospitalizations for HF, respectively (rate ratio, 0.85). 
NYHA class improved in 15% of the patients in the 
sacubitril–valsartan group and in 12.6% of those in the 
valsartan group (odds ratio, 1.45); renal function worsened 
in 1.4% and 2.7%, respectively (HR, 0.50). The mean 
change in quality of life score at 8 months was 1.0 point 
higher in the sacubitril–valsartan group. Patients in the 
sacubitril–valsartan group had a higher incidence of 
hypotension and angioedema and a lower incidence of 
hyperkalemia. Among 12 prespecified subgroups, there 
was suggestion of heterogeneity with possible benefit with 
sacubitril–valsartan in patients with lower ejection fraction 
and in women (Solomon SD et al, N Engl J Med 2019; 
381:1609-20) 
 
Swedish Heart Failure Registry: ICD was Underused 
for Primary Prevention, Although it was Associated 
With Reduced Short- and Long-Term All-Cause 
Mortality Across all Investigated Subgroups  
Of 16,702 eligible patients, only 1599 (10%) had an 
ICD. After matching, 1305 ICD recipients were compared 
with 1305 nonrecipients. ICD use was associated with a 
reduction in all-cause mortality risk within 1 year (hazard 
ratio-HR, 0.73) and 5 years (HR, 0.88). Results were 
consistent in all subgroups including patients with vs 
without ischemic heart disease, men vs women, those aged 
<75 vs ≥75 years, those with earlier vs later enrollment in 
the Swedish heart failure registry, and patients with vs 
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without cardiac resynchronization therapy (Schrage B et 
al, Circulation 2019;140:1530–1539).  
 
Patients With Implantable Electronic Devices: There is 
an Interaction Between AF Duration and CHA2DS2-
Vasc Score That Can Further Risk-Stratify Patients 
With AF for Stroke and Systemic Embolism (SSE) 
Among 21,768 nonanticoagulated patients with 
cardiovascular implantable electronic devices (age, 
68.6±12.7 years; 63% male), both increasing AF duration 
(P<0.001) and increasing CHA2DS2-VASc score 
(P<0.001) were significantly associated with annualized 
risk of SSE. SSE rates were low in patients with a 
CHA2DS2-VASc score of 0 to 1 regardless of device-
detected AF duration. However, stroke risk crossed an 
actionable threshold defined as >1%/y in patients with a 
CHA2DS2-VASc score of 2 with >23.5 h of AF, those with 
a CHA2DS2-VASc score of 3-4 with >6 min of AF, and 
patients with a CHA2DS2-VASc score ≥5 even with no AF. 
(Kaplan RM et al, Circulation 2019;140: 1639–46). 
 
AUGUSTUS Trial: A Regimen of Apixaban and a 
P2Y12 Inhibitor Without Aspirin Provides Superior 
Safety and Similar Efficacy in Patients With AF Who 
Have ACS, Whether Managed Medically or With PCI, 
and Those Undergoing Elective PCI Compared With 
Regimens That Include VKAs, Aspirin, or Both  
Of 4614 patients enrolled, 1097 (23.9%) had ACS 
treated medically and 1714 (37.3%) with PCI, while 1784 
(38.8%) had elective PCI. Apixaban compared with 
vitamin K antagonist (VKA) reduced major or clinically 
relevant nonmajor bleeding in patients with ACS treated 
medically (hazard ratio-HR, 0.44), patients with ACS 
treated with PCI (HR, 0.68), and patients having elective 
PCI (HR, 0.82; Pinteraction=0.052) and reduced death or 
hospitalization in the ACS treated medically (HR, 0.71), 
ACS treated with PCI (HR, 0.88), and elective PCI (HR, 
0.87; Pinteraction=0.345) groups. Compared with VKAs, 
apixaban resulted in a similar effect on death and ischemic 
events in all 3 groups (Pinteraction=0.356). Aspirin had a 
higher rate of bleeding in all 3 groups. For the same 
comparison, there was no difference in outcomes among 
the 3 groups for the composite of death or hospitalization 
and death and ischemic events (Windecker S et al, 
Circulation 2019;140:1921–32).  
 
EXCEL: In Patients With Left Main Disease of Low or 
Intermediate Anatomical Complexity, No Significant 
Difference Between PCI and CABG in Death, Stroke, 
or Myocardial Infarction at 5 Years 
 
Among 1905 patients with left main disease of low or 
intermediate anatomical complexity randomized to PCI 
with everolimus-eluting stents (n=948) or CABG (n=957), 
at 5 years, a primary outcome event (death, stroke, or MI) 
had occurred in 22% vs 19.2% (P=0.13). Death from any 
cause occurred more frequently in the PCI group than in 
the CABG group (in 13.0% vs 9.9%). In the PCI and 
CABG groups, the incidences of definite cardiovascular 
death (5.0% and 4.5%, respectively) and MI (10.6% and 
9.1%;) were not significantly different. All 
cerebrovascular events were less frequent after PCI than 
after CABG (3.3% vs 5.2%), although the incidence of 
stroke was not significantly different between the 2 groups 
(2.9% and 3.7%). Ischemia-driven revascularization was 
more frequent after PCI than after CABG (16.9% vs 10%) 
(Stone GW et al, N Engl J Med 2019; 381:1820-30). 
 
THEMIS: In Patients With Stable Coronary Artery 
Disease and Diabetes Without a History of Myocardial 
Infarction or Stroke, Those Who Received Ticagrelor 
Plus Aspirin Had a Lower Incidence of Ischemic 
Cardiovascular (CV) Events But a Higher Incidence of 
Major Bleeding Compared to Placebo Plus Aspirin  
Among 19,220 patients randomized, over a median of 
39.9 months, where treatment discontinuation was more 
frequent with ticagrelor than placebo (34.5% vs. 25.4%), 
the incidence of ischemic CV events was lower in the 
ticagrelor than in the placebo group (7.7% vs 8.5%; hazard 
ratio-HR, 0.90; P=0.04), whereas the incidence of TIMI 
major bleeding was higher (2.2% vs 1.0%; HR, 2.32; 
P<0.001), as was the incidence of intracranial hemorrhage 
(0.7% vs 0.5%; HR, 1.71; P=0.005). There was no 
difference in the incidence of fatal bleeding (0.2% vs 
0.1%). The incidence of an exploratory composite 
outcome of irreversible harm (death from any cause, 
myocardial infarction, stroke, fatal bleeding, or 
intracranial hemorrhage) was similar in the 2 groups 
(10.1% vs 10.8%) (Steg PG et al, N Engl J Med 2019; 
381:1309-20).  
 
ISAR-REACT 5: Among Patients With Acute 
Coronary Syndromes (ACS) With or Without ST-
Elevation, the Incidence of Death, MI, or Stroke Was 
Lower in Those Who Received Prasugrel vs Ticagrelor, 
and the Incidence of Major Bleeding was Similar  
Among 4018 patients randomized, a primary end-
point event occurred in 9.3% in the ticagrelor group and in 
6.9% in the prasugrel group (hazard ratio-HR, 1.36; 
P=0.006). The respective incidences of the individual 
components of the primary end point in the ticagrelor 
group and the prasugrel group were as follows: death, 
4.5% vs 3.7%; MI, 4.8% vs 3.0%; and stroke, 1.1% vs 
1.0%. Definite or probable stent thrombosis occurred in 
1.3% vs 1.0%, and definite stent thrombosis occurred in 
1.1% vs 0.6%, respectively. Major bleeding was observed 
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in 5.4% vs 4.8% (HR, 1.12; P=0.46) (Schüpke S et al, N 
Engl J Med 2019; 381:1524-34).  
 
TWILIGHT: Among High-Risk Patients Who 
Underwent PCI and Completed 3 Months of Dual 
Antiplatelet Therapy, Ticagrelor Monotherapy was 
Associated With a Lower Incidence of Clinically 
Relevant Bleeding Than Ticagrelor Plus Aspirin, With 
No Higher Risk of Death, MI, or Stroke  
 
Among 9006 enrolled patients, 7119 underwent 
randomization after 3 months. Between randomization and 
1 year, the incidence of the primary end point was 4% 
among patients randomized to ticagrelor plus placebo and 
7.1% among patients assigned to ticagrelor plus aspirin 
(hazard ratio-HR, 0.56; P<0.001). The difference in risk 
between the groups was similar for BARC type 3 or 5 
bleeding (1% vs 2.0%; HR, 0.49). The incidence of death 
from any cause, nonfatal myocardial infarction (MI), or 
nonfatal stroke was 3.9% in both groups (HR, 0.99; 
P<0.001 for noninferiority) (Mehran R et al, N Engl J Med 
2019; 381:2032-2042) 
 
Apple Heart Study: Probability of Receiving an 
Irregular Pulse Notification by a Smart Watch Was 
Low, and of Those, Only 34% Had Atrial Fibrillation 
(AF) on Subsequent ECG Patch Readings  
Among 419,297 participants, over a median of 117 
days of monitoring, 2161 (0.52%) received notifications of 
irregular pulse. Among the 450 participants who returned 
ECG patches, AF was present in 34% overall and in 35% 
of participants >65 years of age. Among participants who 
were notified of an irregular pulse, the positive predictive 
value was 0.84 for observing AF on the ECG 
simultaneously with a subsequent irregular pulse 
notification and 0.71 for observing AF on the ECG 
simultaneously with a subsequent irregular tachogram. 
There were no reports of serious app-related adverse 
events (Perez MV et al, N Engl J Med 2019; 381:1909-17).  
 
CRICS-TRIGGERSEP: Among Patients with Coma 
Resuscitated from Cardiac Arrest With Nonshockable 
Rhythm (Asystole or Pulseless Electrical Activity), 
Moderate Therapeutic Hypothermia at 33°C for 24 h 
Led to a Higher Percentage of Favorable Neurologic 
Outcome at Day 90 Than Targeted Normothermia  
Among 581 patients randomized to moderate 
therapeutic hypothermia (33°C during the first 24 h) or 
targeted normothermia (37°C), on day 90, a total of 29 of 
284 patients (10.2%) in the hypothermia group were alive 
with a cerebral performance score of 1 or 2 (lower 
disability), as compared with 17 of 297 (5.7%) in the 
normothermia group (P=0.04). Mortality at 90 days did not 
differ between the 2 groups (81.3% vs 83.2%). The 
incidence of prespecified adverse events did not differ 
between groups (Lascarrou J-B et al, N Engl J Med 2019; 
381:2327-37).  
 
COLCOT: Among Patients With a Recent Myocardial 
Infarction (MI), Colchicine (0.5 mg qd) Led to a Lower 
Risk of Ischemic Cardiovascular Events Than Placebo  
Among 4745 MI patients assigned to colchicine 
(n=2366) or placebo (n=2379), over a median of 22.6 
months, the primary end point (CV death, resuscitated 
cardiac arrest, MI, stroke, or urgent hospitalization for 
angina leading to coronary revascularization) occurred in 
5.5% of the patients in the colchicine group, as compared 
with 7.1% of those in the placebo group (hazard ratio-HR, 
0.77; P=0.02). The HRs were 0.84 for CV death, 0.83 for 
resuscitated cardiac arrest, 0.91 for MI, 0.26 for stroke, and 
0.50 for urgent hospitalization for angina leading to 
coronary revascularization. Diarrhea was reported in 9.7% 
of the patients in the colchicine group and in 8.9% of those 
in the placebo group (P=0.35). Pneumonia was reported as 
a serious adverse event in 0.9% of the patients in the 
colchicine group and in 0.4% of those in the placebo group 
(P=0.03) (Tardif JC et al, N Engl J Med 2019; 381:2497-
2505) 
 
BIOSTEMI: Biodegradable Versus Durable Polymer 
Sirolimus-Eluting Stents Superior in Patients With 
STEMI Regarding Target Lesion Failure at 1 Year 
 
Among 1300 patients (1623 lesions) with acute MI 
assigned to biodegradable (649 patients and 816 lesions) 
or durable polymer everolimus-eluting stents (651 patients 
and 806 lesions), at 12 months, the primary composite 
endpoint of target lesion failure occurred in 25 (4%) of 649 
patients treated with biodegradable and 36 (6%) of 651 
patients treated with durable polymer everolimus-eluting 
stents (rate ratio 0ꞏ59). Cardiac death, target vessel 
myocardial reinfarction, clinically-indicated target lesion 
revascularization, and definite stent thrombosis were 
similar between the two treatment groups (Iglesias JF et al, 
Lancet 2019; 394:1243-53). 
 
SYNTAX/10-Year Follow-Up: At 10 Years, No 
Difference in All-Cause Death Between PCI Using 
First-Generation Paclitaxel-Eluting Stents and CABG. 
However, CABG Provided a Survival Benefit in 
Patients With 3-Vessel, But not Left Main Disease   
Among 1800 patients randomly assigned to PCI 
(n=903) or CABG (n=897), at 10 years, 27% had died after 
PCI and 24% after CABG (hazard ratio-HR 1.17, 
p=0ꞏ092). Among patients with 3-vessel disease, 28% had 
died after PCI vs 21% after CABG (HR 1.41), and among 
patients with left main disease, 26% had died after PCI vs 
28% after CABG (HR 0.90, p interaction=0ꞏ019). There was 
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no treatment-by-subgroup interaction with diabetes (p 
interaction=0ꞏ66) and no linear trend across SYNTAX score 
tertiles (p trend=0ꞏ30) (Thuijs DJFM et al, Lancet 2019; 
394:1325-34).  
 
EU-CERT-ICD: Periodic Repolarization Dynamics 
Predict Mortality Reductions Associated With 
Prophylactic Implantation of ICDs and Could Help 
Guide Treatment Decisions on Prophylactic ICD  
 
Among 1371 patients, of whom 968 underwent ICD 
implantation, and 403 were treated conservatively, over a 
median of 2.7 years in the ICD group and 1.2 years in the 
control group, death rate was 14% vs 16% respectively. 
We noted a 43% reduction in mortality in the ICD group 
compared with the control group (adjusted hazard ratio - 
HR 0.57; p=0ꞏ0008). Periodic repolarization dynamics 
significantly predicted the treatment effect of ICDs on 
mortality (adjusted p=0ꞏ0307). The mortality benefits 
associated with ICD implantation were greater in patients 
with periodic repolarization dynamics of >7.5 deg (n=199; 
adjusted HR 0.25 for the ICD group vs the control group; 
p<0ꞏ0001) than in those with periodic repolarization 
dynamics <7.5 deg (n=1166; adjusted HR 0.69; p=0ꞏ0492; 
p interaction=0ꞏ0056). The number needed to treat was 18.3 in 
patients with periodic repolarization dynamics < 7.5 deg 
and 3.1 in those with periodic repolarization dynamics of 
>7.5 deg (Bauer A et al, Lancet 2019;394: 1344-51)  
 
AMBER: In Patients With Resistant Hypertension and 
Chronic Kidney Disease, the Potassium Binder, 
Patiromer, Enabled More Patients to Continue 
Treatment With Spironolactone With Less 
Hyperkalemia 
Among 295 patients randomly assigned to 
spironolactone in addition to double-blind treatment with 
either placebo (n=148) or patiromer (n=147), at week 12, 
66% in the placebo group and 86% in the patiromer group 
remained on spironolactone (between-group difference 
19ꞏ5%; p<0ꞏ0001). Adverse events were mostly mild or 
moderate in severity and occurred in 53% vs 56% of 
patients (Agarwal R et al, Lancet 2019; 394: 1540-50). 
 
A Comprehensive Framework, Systematic, Large-
Scale Cohort Study Supports Equivalence Between 
Drug Classes for Initiating Monotherapy for 
Hypertension - In Keeping With Current Guidelines, 
With the Exception of Thiazide or Thiazide-Like 
Diuretics Superiority to Angiotensin-Converting 
Enzyme Inhibitors and the Inferiority of Non-
Dihydropyridine Calcium Channel Blockers  
A systematic, large-scale cohort study designed to 
estimate the relative risks of three primary (acute 
myocardial infarction, hospitalization for heart failure, and 
stroke) and six secondary effectiveness and 46 safety 
outcomes comparing all first-line classes across a global 
network, used 4.9 million patients, generating 22,000 
calibrated, propensity-score-adjusted hazard ratios (HRs) 
comparing all classes and outcomes across databases. Most 
estimates revealed no effectiveness differences between 
classes; however, thiazide or thiazide-like diuretics 
showed better primary effectiveness than angiotensin-
converting enzyme inhibitors (ACEI): acute MI (HR 0.84), 
hospitalization for heart failure (0.83), and stroke (0.83) 
risk while on initial treatment. Safety profiles also favored 
thiazide or thiazide-like diuretics over ACEI. The non-
dihydropyridine calcium channel blockers were 
significantly inferior to the other four classes (Suchard MA 
et al, Lancet 2019;394: 1816-26).  
 
TRILUMINATE: The TriClip System Appears to be 
Safe and Effective at Reducing Tricuspid 
Regurgitation by at Least One Grade  
Among 85 patients (age 77.8±7.9 years; 66% women) 
who underwent successful TriClip implantation (clip-
based edge-to-edge repair), tricuspid regurgitation severity 
was reduced by at least one grade at 30 days in 71 (86%) 
of 83 patients who had available echocardiogram data and 
imaging. One patient withdrew before 6-month follow-up 
without having had a major adverse event and was 
excluded from analysis of the primary safety endpoint. At 
6 months, three (4%) of 84 patients experienced a major 
adverse event, which was less than the prespecified 
performance goal of 39% (p<0.0001). Single leaflet 
attachment occurred in five (7%) of 72 patients. No 
periprocedural deaths, conversions to surgery, device 
embolizations, MIs, or strokes occurred. At 6 months, all-
cause mortality had occurred in four (5%) of 84 patients 
(Nickenig G et al, Lancet 2019; 394: 2002-11).  
 
E-VALI or VALI (e-Cigarettes or Vaping Associated 
Lung Injury) is an Emerging Illness Associated With 
Severe Lung Injury and Constitutional and 
Gastrointestinal Symptoms, With a Broad Spectrum of 
Severity of Illness in Patients Treated With Antibiotics 
and Steroids / Despite Improvement, at Short-Term 
Follow-Up Many Patients Have Residual 
Abnormalities  
Of 60 patients presented with EVALI at 13 hospitals 
or outpatient clinics, 33 (55%) were admitted to an 
intensive care unit (ICU). 53 (88%) patients presented with 
constitutional symptoms, 59 (98%) with respiratory 
symptoms, and 54 (90%) with gastrointestinal symptoms. 
54 (90%) of 60 were given antibiotics and 57 (95%) were 
given steroids. Six (10%) of 60 patients were readmitted to 
an ICU or hospital within 2 weeks, 3 (50%) of whom had 
relapsed with vaping or e-cigarette use. Of 26 patients who 
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were followed up within 2 weeks, despite clinical and 
radiographic improvement in all, many had residual 
abnormalities on chest radiographs (10 of 15 or 67%) and 
pulmonary function tests (6 of 9 or 67%). Two patients 
died and EVALI was thought to be a contributing factor, 
but not the cause of death, for both (Blagev DP et al, 
Lancet 2019; 394:2073-83).  
 
AIMS: Irbesartan is Associated With a Reduction in 
the Rate of Aortic Dilatation in Children and Young 
Adults With Marfan Syndrome and Could Reduce the 
Incidence of Aortic Complications  
Among 192 participants (median age 18 years; 52% 
females; mean blood pressure 110/65 mmHg; 56% on β-
blockers; mean baseline aortic root diameter 34.4 mm) 
randomly assigned to irbesartan (n=104) or placebo 
(n=88), followed for up to 5 years, the mean rate of aortic 
root dilatation was 0.53 mm per year in the irbesartan 
group compared with 0.74 mm per year in the placebo 
group (p=0.030). The rate of change in aortic Z score was 
also reduced by irbesartan (p=0.035). Irbesartan was well 
tolerated with no observed differences in rates of serious 
adverse events (Mullen M et al, Lancet 2019;394:2263-70) 
 
A Nationwide Population-Based Study of ~10 Million 
Persons: Altered Risk for Cardiovascular (CV) Events 
with Changes in Metabolic Syndrome (MetS) Status / 
Recovery from MetS was Significantly Associated With 
Decreased Risk for MACE, whereas Development of 
MetS was Associated with Increased Risk  
The MetS status was determined for 9,553,042 
persons. At a median of 3.54 years, the MetS-recovery 
group (incidence rate, 4.55 per 1000 person-years) had a 
lower MACE risk (adjusted incidence rate ratios-IRR, 
0.85) than that of the MetS-chronic group (incidence rate, 
8.52 per 1000 person-years). The MetS-developed group 
(incidence rate, 6.05 per 1000 person-years) had a 
significantly higher MACE risk (IRR, 1.36) than that of the 
MetS-free group (incidence rate, 1.92/1000 person-years). 
Among the MetS components, change in hypertension was 
associated with the largest difference in MACE risk (Park 
S et al, Ann Intern Med 2019;171:875–84) 
  
Important Review and Other Articles  
 
ACC/AHA/HRS vs ESC Syncope Guidelines (Goldberger ZD 
et al, J Am Coll Cardiol 2019;74:2410-23) 
 
● Resuscitation Guideline Update (Circulation 2019;140: 
e826–e938)  
 
● CV toxicities of immune check point inhibitors (Mangieri A 
et al, J Am Coll Cardiol 2019; 74: 2088-2101) 
 
● Thrombotic vs bleeding risk after TAVI (January CT et al, 
Circulation 2019;140:e125–e151) 
 
● Anticoagulation in concomitant chronic kidney disease and 
AF (Kumar S et al, Eur Heart J 2019;74:2204-15) 
 
● Advanced heart failure therapies for adults with congenital 
heart disease (Givertz MM et al, J Am Coll Cardiol 2019; 
74:2295-2312)  
 
● SGLT2 inhibitors and cardiorenal protection (Cherney DZ et 
al, J Am Coll Cardiol 2019;74:2511-24) 
 
● Primary aldosteronism (Rossi GP et al, J Am Coll Cardiol 
2019;74:2799-2811) 
 
● Left bundle branch pacing (Zhang S et al, J Am Coll Cardiol 
2019;74:3039-49) 
 
● Ischemic stroke risk in AF (Alkhouli M et al, J Am Coll 
Cardiol 2019;74:3050-65) 
 
● Aortic stenosis and cardiac amyloidosis (Ternacle J et al, J Am 
Coll Cardiol 2019;74:2638-51) 
 
● Chimeric Antigen Receptor (CAR) T-cell therapy for cancer 
and heart (Ganatra S et al, J Am Coll Cardiol 2019;74:3153-63) 
 
● Mitochondria and CV system (Tian R et al, Circulation 
2019;140:1205-16) 
 
● Arterial grafts for coronary bypass (Gaudino M et al, 
Circulation 2019;140:1273-84) 
 
● Interventional therapies in pulmonary embolism (Giri J et al, 
Circulation 2019;140:e774–e801) 
 
● Multimodality imaging in infective endocarditis (Erba PA et 
al, Circulation 2019;140:1753–65) 
 
● Searching for AF post stroke (Schnabel RB, et al, Circulation 
2019;140:1834–50) 
 
● Subclinical and device-detected AF (Noseworthy, PA et al, 
Circulation 2019;140:e944–e963) 
 
● Lipid management for prevention of CVD (Michos ED et al, 
N Engl J Med 2019; 381:1557-1567) 
 
● Lay responder care for out-of-hospital cardiac arrest (Brady 
WJ et al, N Engl J Med 2019; 381:2242-51) 
 
Red and processed meat consumption and risk for all-cause 
mortality and cardiometabolic outcome (Zeraatkar D et al, Ann 
Intern Med 2019;171:703–10) 
 
Reduction of red and processed meat intake and cancer mortality 
and incidence (Han MA et al, Ann Intern Med 2019;171:711–20) 
 
European position paper on management of patients with patent 
foramen ovale (Pristipino C et al, Eur Heart J 2019;40:3182-95) 
 
● Treatment of cardiac transthyretin amyloidosis (Emdin M et 
al, Eur Heart J 2019; 40: 3699-3706) 
 
● Immunotherapy for CV disease (Lutgens E et al, Eur Heart J 
2019;40:3937-46) 
 
● Winter swimming: body hardening and cardiorespiratory 
protection (Manolis AS et al, Curr Sports Med Rep 2019;18:401-
415) 
